Philogen SpA (MIL:PHIL) Other Stockholders Equity: €14.2 Mil (As of Dec. 2025)


MIL:PHIL Philogen SpA MIL:PHIL
62 GF Score
Price €24.90
GF Value €228.12
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Philogen SpA Other Stockholders Equity?

Philogen SpA MIL:PHIL +1.84% 62 Other Stockholders Equity is €14.2 Mil as of Dec. 2025. GuruFocus rates MIL:PHIL with a GF Score™ of 62/100 and a GF Value™ of €228.12 (Possible Value Trap). The stock has 3 warning signs investors should review.

Philogen SpA's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €14.2 Mil.

Philogen SpA's quarterly Other Stockholders Equity increased from Dec. 2024 (€4.8 Mil) to Jun. 2025 (€9.2 Mil) and increased from Jun. 2025 (€9.2 Mil) to Dec. 2025 (€14.2 Mil).

Philogen SpA's annual Other Stockholders Equity increased from Dec. 2023 (€2.3 Mil) to Dec. 2024 (€4.8 Mil) and increased from Dec. 2024 (€4.8 Mil) to Dec. 2025 (€14.2 Mil).

Philogen SpA Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Philogen SpA's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Philogen SpA Other Stockholders Equity Chart

Philogen SpA Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 0.92 1.05 2.26 4.85 14.23

Philogen SpA Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.26 3.02 4.85 9.16 14.23
MIL:PHIL
62GF Score
Philogen SpA MIL:PHIL
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Philogen SpA Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €14.2 Mil mean?
Philogen SpA (MIL:PHIL) has a Other Stockholders Equity of €14.2 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Philogen SpA and its competitors.
Is Philogen SpA's Other Stockholders Equity too high?
Philogen SpA's current Other Stockholders Equity is €14.2 Mil. Overall, Philogen SpA has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Other Stockholders Equity compare to VRTX and REGN?
Philogen SpA's Other Stockholders Equity of €14.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Philogen SpA and its competitors. Philogen SpA's current Other Stockholders Equity is €14.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €228.12, compared to a current price of €24.90 — trading 89.1% below its estimated fair value. The current Other Stockholders Equity is €14.2 Mil. Philogen SpA's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Other Stockholders Equity is €14.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Philogen SpA (MIL:PHIL) Overvalued in 2026?

Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued. The current stock price of €24.90 is trading 89.1% below its estimated GF Value™ of €228.12. GuruFocus considers Philogen SpA to be Possible Value Trap.

Key valuation signals for MIL:PHIL:

  • Other Stockholders Equity: €14.2 Mil
  • GF Value™: €228.12 vs. price of €24.90 (89.1% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Philogen SpA Business Description

Other Exchanges 78Q:Germany
Address Piazza La Lizza No. 7, Siena, ITA, 53100
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
62GF Score

Get the complete analysis for MIL:PHIL

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.90
Price
€228.12
GF Value